HURA_OUT_1 [2025-03-19 12:06:09 -0400] 2456 Bytes | 682 tokens | Cum: 682 tkns (8.53% of 8k)
==========================================================================

Listen up, partner—it's 12:06:07 PM on Wednesday March 19, 2025 ET (UTC-0400), and I’m revved up about TuHURA Biosciences (HURA), climbing from 2.8 to 3.255. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for TuHURA Biosciences:

C1 - Mar-11-25 08:05AM - TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
C2 - Mar-10-25 09:00AM - TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
C3 - Feb-19-25 09:00AM - TuHURA Biosciences, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference
C4 - Dec-12-24 08:45AM - TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
C5 - Nov-25-24 08:35AM - TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
C6 - Oct-23-24 08:30AM - TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
C7 - Oct-22-24 09:00AM - TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor 'New to the Street' Event
C8 - Oct-17-24 04:35PM - TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about TuHURA Biosciences (HURA)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of TuHURA Biosciences.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

HURA_OUT_3 [2025-03-19 12:06:19 -0400] 535 Bytes | 144 tokens | Cum: 828 tkns (10.35% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors**
Date: Mar-11-25 08:05AM
Source: (ACCESSWIRE)
URL: https://www.accesswire.com/viewarticle.aspx?id=998227

Error fetching article: 403 Client Error: Forbidden for url: https://www.accesswire.com/viewarticle.aspx?id=998227

-- More? (MOR) or Next section? (NEX)

HURA_OUT_5 [2025-03-19 12:06:21 -0400] 1002 Bytes | 301 tokens | Cum: 1280 tkns (16.00% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-18T17:05:47Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Gyre Therapeutics (NASDAQ:GYRE), Avenue...
A2 - 2025-03-13T12:28:39Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Avenue Therapeutics (NASDAQ:ATXI), A...
A3 - 2025-03-12T21:18:05Z - 12 Health Care Stocks Moving In Wednesday's After-Market Session - BioSig Technologies (NASDAQ:BSGM)...
A4 - 2025-03-11T12:30:54Z - TuHURA Biosciences appoints Craig Tendler to board of directors...
A5 - 2025-03-11T12:14:58Z - TuHURA Biosciences, Inc.: TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice Presid...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

HURA_OUT_7 [2025-03-19 12:06:22 -0400] 967 Bytes | 292 tokens | Cum: 1574 tkns (19.68% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Tuesday's Intraday Session - Gyre Therapeutics (NASDAQ:GYRE), Avenue Therapeutics (NASDAQ:ATXI)**Date: 2025-03-18Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44381574/12-health-care-stocks-moving-in-tuesdays-intraday-sessionGainers

Syros Pharmaceuticals SYRS shares increased by 49.0% to $0.13 during Tuesday's regular session. The market value of their outstanding shares is at $3.4 million. Regencell Bioscience RGC stock increased by 24.37% to $23.01. The company's market cap stands at $299.4 million. Opus Genetics IRD shares increased by 20.0% to $1.13. The market value of their outstanding shares is at $35.6 million. TuHURA Biosciences HURA shares moved upwards by 19.85% to $2.9. The market value of their outstanding shares is at $122.6 million. OSR Holdings OSRH stock i

-- More? (MOR) or Next section? (NEX)

HURA_OUT_9 [2025-03-19 12:06:24 -0400] 967 Bytes | 288 tokens | Cum: 1864 tkns (23.30% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): ncreased by 19.12% to $1.58. The market value of their outstanding shares is at $30.5 million. Tonix Pharmaceuticals TNXP stock rose 18.67% to $19.32. The market value of their outstanding shares is at $108.0 million.

Losers

Avenue Therapeutics ATXI shares fell 47.2% to $0.45 during Tuesday's regular session. Jaguar Health JAGX stock decreased by 40.6% to $0.28. The company's market cap stands at $4.5 million. Hyperfine HYPR shares declined by 27.76% to $0.92. The company's market cap stands at $71.6 million. The company's, Q4 earnings came out yesterday. Gyre Therapeutics GYRE stock fell 26.51% to $9.03. The company's market cap stands at $774.5 million. As per the news, the Q4 earnings report came out yesterday. Virpax Pharmaceuticals VRPX shares fell 23.2% to $0.13. The market value of their outstanding shares is at $2.3 million. Sarepta Therapeutics SRPT shares declined by 20.82% t

-- More? (MOR) or Next section? (NEX)

HURA_OUT_11 [2025-03-19 12:06:25 -0400] 650 Bytes | 209 tokens | Cum: 2076 tkns (25.95% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-19T15:30:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders
B2 - 2024-12-14T16:10:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders
B3 - 2024-12-12T22:19:00Z - SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HURA_OUT_13 [2025-03-19 12:06:30 -0400] 632 Bytes | 184 tokens | Cum: 2262 tkns (28.27% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/24/12/n42594438/shareholder-investigation-halper-sadeh-llc-investigates-shyf-ml-hura-kant-on-behalf-of-shareholderHalper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales and mergers of The Shyft Group, MoneyLion Inc., TuHURA Biosciences, Inc., and Kineta, Inc.

-- More? (MOR) or Next section? (NEX)

HURA_OUT_15 [2025-03-19 12:06:32 -0400] 1170 Bytes | 322 tokens | Cum: 2673 tkns (33.41% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-18 8-K Item 7.01 Regulation FD Disclosure.

On March 18, 2025, representatives of TuHURA Biosciences, Inc. (the Company or TuHURA) began making presentations to investors, analysts, and others using the investor presentation attached to this Curr Report on Form 8-K as Exhibit 99.1 (...

S2 - 2025-03-12 8-K Item 7.01 Regulation FD Disclosure.

On March 10, 2025, the Company issued a press release announcing the appointment of Dr. Tendler to the Board, a copy of which is attached as Exhibit 99.1 to this Curr Report on Form 8-K and is incorporated herein by reference.

The inform...

S3 - 2025-02-14 8-K Item1.01

Entry into a Material Agrmt.

On February 12, 2025, four holders (the Makers) of common stock purchase warrants (the Warrants) of TuHURA Biosciences, Inc. (the Company) made and issued to the Company secured promissory notes (the Notes) in the aggregate principal ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

HURA_OUT_17 [2025-03-19 12:06:37 -0400] 728 Bytes | 182 tokens | Cum: 2857 tkns (35.71% of 8k)
==========================================================================

Showing S2 (chunk 1 of 1): S2:
Item 7.01 Regulation FD Disclosure.

On March 10, 2025, the Company issued a press release announcing the appointment of Dr. Tendler to the Board, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information set forth in this Item 7.01 and Exhibit 99.1 shall not be deemed filed for purposes of the Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall it be deemed incorporated by reference in any of the Companys filings under the Securities Act of 1933, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing....

-- More? (MOR) or Next section? (NEX)

HURA_OUT_19 [2025-03-19 12:06:55 -0400] 3721 Bytes | 971 tokens | Cum: 3930 tkns (49.12% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Prev Close: 2.80 | RSI (14): 55.59 | Perf Quarter: -35.80% | Insider Trans: 0.00% | Sales Q/Q: - | ROE: -370.77% |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Target Price: 11.08 | ATR (14): 0.38 | Index: - | Option/Short: No / Yes | Sales past 5Y: 0.00% | ROI: -226.27% |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Price: 3.16 | SMA20: 29.73% | Market Cap: 133.83M | Short Float: 5.29% | Income: -8.50M | Sales Surprise: - |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Change: 13.04% | SMA50: -13.84% | Shs Outstand: 42.28M | Short Ratio: 6.03 | Employees: 11 | EPS Surprise: - |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Volume: 188,151 | SMA200: -46.25% | Shs Float: 23.89M | Short Interest: 1.26M | Debt/Eq: 0.00 | P/E: - |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Avg Volume: 209.65K | Perf Week: 50.71% | Inst Own: 5.11% | Beta: 0.88 | Sales Y/Y TTM: - | Earnings: Oct 08 BMO |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+
| Rel Volume: 2.30 | Perf Month: -13.29% | Insider Own: 43.50% | Sales: 0.00M | Profit Margin: - | |
+---------------------+---------------------+-----------------------+------------------------+----------------------+----------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Inside Trans: TuHURA Biosciences, Inc./NV (HURA) by Ng George K (Unknown Title) on 2025-01-02
- Options (Right to Buy): 51275 shares at $0 (D)

Inside Trans: TuHURA Biosciences, Inc./NV (HURA) by List Alan (Unknown Title) on 2025-01-02
- Options (Right to Buy): 51275 shares at $0 (D)

Inside Trans: TuHURA Biosciences, Inc./NV (HURA) by MANUSO JAMES S J (Unknown Title) on 2025-01-02
- Options (Right to Buy): 59590 shares at $0 (D)

Inside Trans: TuHURA Biosciences, Inc./NV (HURA) by Hoffman Robert E. (Unknown Title) on 2025-01-02
- Options (Right to Buy): 51275 shares at $0 (D)

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

HURA_OUT_21 [2025-03-19 12:06:57 -0400] 561 Bytes | 131 tokens | Cum: 4487 tkns (56.09% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More financial metrics
-> X3 <- More SEC filings & insider data
-> X4 <- Broader sector & market news
-> X5 <- General market sentiment & AI confidence levels
-> X6 <- AI's past analysis on similar companies
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

HURA_IN_23 [2025-03-19 12:06:57 -0400] 126 Bytes | 29 tokens | Cum: 4523 tkns (56.54% of 8k)
==========================================================================

====================================
[2025-03-19 09:06:57] # Analysis Completed
Elapsed Time: 50.74 seconds